In June 2025, the NPPA revised the ceiling price for azathioprine tablets, reducing it by 5% to enhance affordability for patients. This adjustment reflects the Indian government's commitment to making essential medicines more accessible.
In September 2025, the WHO updated its Model List of Essential Medicines, reaffirming azathioprine's inclusion. This update underscores the drug's continued importance in global healthcare and may influence procurement policies in various countries.
In November 2025, the EMA issued a new guideline on the quality requirements for azathioprine-containing products, emphasizing the need for stringent impurity control. This guideline aims to ensure the safety and efficacy of azathioprine formulations within the European market.
In January 2026, the FDA approved a new generic version of azathioprine tablets, further increasing competition in the U.S. market. This approval is expected to contribute to lower prices and improved patient access to azathioprine.
In February 2026, the CDSCO implemented a new requirement for azathioprine manufacturers to submit periodic safety update reports (PSURs) to monitor the drug's safety profile. This regulatory change aims to enhance pharmacovigilance and ensure patient safety.
These developments highlight the dynamic regulatory environment surrounding azathioprine and the ongoing efforts to ensure its quality, safety, and accessibility in both domestic and international markets.
